AbbVie announced that Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection) under the Priority Review process. ELAHERE is an antibody-drug conjugate (ADC) designed to treat adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three prior systemic treatment regimens.
Ovarian cancer remains a significant challenge due to its often vague symptoms, late diagnosis, and development of resistance to standard treatments. Tania Vrionis, CEO of Ovarian Cancer Canada, highlighted that the approval of ELAHERE offers an important new treatment option that could improve outcomes for patients no longer responding to surgery and chemotherapy.
Dr. Shannon Salvador, President of the Society of Gynecologic Oncologists of Canada, emphasized the importance of this approval, calling it a critical advancement for patients with platinum-resistant ovarian cancer—a form of gynecological cancer with the lowest survival rates in Canada. She noted that ELAHERE has been shown to extend survival, providing hope for patients facing limited effective therapies.
Rami Fayed, Vice President and General Manager of AbbVie Canada, described ELAHERE® as the first new treatment in over a decade for this type of ovarian cancer. He reaffirmed AbbVie’s commitment to developing innovative therapies for difficult-to-treat cancers to improve patient outcomes and quality of life.
This approval marks a significant milestone for ovarian cancer care in Canada, providing a new option for patients with limited treatment choices.